InvivoCure | Los Angeles, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have New York Heart Association Class II to III heart failure
Have left ventricular ejection fraction (LVEF) ≥ 50%
KCCQ-CSS ≤ 80
6MWD must be all of the following:
Have documented evidence of at least one of the following:
Stable dose of heart failure medications
Body mass index (BMI) ≥ 23 kilograms per meter squared (kg/m²)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
540 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Physicians interested in becoming principal investigators please contact; Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal